INDV.L Stock Analysis
IN
Uncovered
Indivior PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. The company is headquartered in Slough, Berkshire. The company went IPO on 2014-12-23. The firm develops medicines to treat addiction and serious mental illnesses. The firm focuses on building a portfolio of opioid dependence treatments. The company has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its SUBLOCADE, SUBUTEX and SUBOXONE are used for the treatment of opioid use disorder (OUD). Its PERSERIS is used for the treatment of Schizophrenia. The firm's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine/ Naloxone Sublingual Film, Buprenorphine/ Naloxone Sublingual Tablet, and Buprenorphine Sublingual Tablet, OPNT003, OPNT002, and OPNT004.